We also show evidence that inhibition of the isopeptidase activity of COPS5 is sufficient to re-sensitize the resistant breast cancer cells to tamoxifen-treatment, providing a potential therapeutic approach for endocrine-resistant breast cancer patients. The gene discussed is COPS5; the disease is breast carcinoma.